Effectiveness of Curcumin in patients with Parkinson's disease
Phase 3
- Conditions
- Parkinson's disease.Parkinson's disease
- Registration Number
- IRCT20171123037600N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients who are diagnosed with Parkinson's disease based on MDS clinical diagnostic criteria for Parkinson's disease and at least 30 years of age
Patients who are receiving dopaminergic treatment and their symptoms are under control
Patients with signed informed consent
Exclusion Criteria
Severe systemic or psychologic disease
History of Gastrointestinal bleeding
Aspirin use over 325mg/day, any anticoagulant or anti-platelet drug use such as heparin or warfarin, antioxidant use except vitamin E up to 2000 IU/day and vitamin C up to 500mg/day
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patients score in MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating) scale. Timepoint: beginning of study, 3 months after drug initiation, 6 months after drug initiation, 9 months after drug initiation. Method of measurement: MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating) scale which is a based on standard questionnaire, interview and neurological examination of the patients.
- Secondary Outcome Measures
Name Time Method